Side-by-side · Research reference

BPC-157vsSermorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed9/53 cited

BPhase 3Reviewed14/43 cited

BPC-157

Stable Gastric Pentadecapeptide · Healing

250–500 mcgDaily doseHwang 2016

Phase 2Evidence levelHwang 2016 Sikiric 2018

~30 minHalf-life (est.)

SQ or IM · Local · Once or twice daily

Sermorelin

GHRH 1-29 fragment · Short-acting

100–500 mcgPer doseMolteno 2013

Phase 3Evidence levelWalker 1994 Molteno 2013

~12 minHalf-lifeMolteno 2013

SQ · Pre-sleep · 1×/day

01Mechanism of Action

Parameter

BPC-157

Sermorelin

Primary target

VEGFR2 / nitric oxide / FAK-paxillin axes (proposed)Chang 2014 Sikiric 2018

Pituitary GHRH receptorWalker 1994

Pathway

Upregulates VEGFR2 → angiogenesis; modulates NO synthase; promotes fibroblast outgrowth via FAK-paxillinChang 2014

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994

Downstream effect

Accelerated tissue repair, reduced inflammation, improved gut barrier integritySikiric 2018

Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013

Feedback intact?

No known endogenous receptor; mechanism still under investigation

Yes — short pulse preserves feedback

Origin

Synthetic pentadecapeptide derived from a sequence in human gastric juice; first characterised by Sikiric et al.Sikiric 2018

Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994

Antibody development

—

02Dosage Protocols

Parameter

BPC-157

Sermorelin

Standard dose

250–500 mcg / dayHwang 2016

Anecdotal community range. Phase 2 trial used 1.0 mg PL-14736 IV/day.

100–500 mcg per injectionMolteno 2013

Frequency

Once or twice daily

Split dosing reported anecdotally for chronic injury.

Once daily, pre-sleep

Lower / starter dose

200 mcg / day

Conservative starter for new users.

100 mcg per dose

Evidence basis

Animal-strong + Phase 2 clinicalSikiric 2018 Hwang 2016

Phase 3 (Geref pediatric); clinical practiceWalker 1994 Molteno 2013

Duration

2–4 weeks (acute injury); 4–8 weeks (chronic)

Anecdotal; no long-term human safety data.

8–12 weeks per cycle

Reconstitution

Bacteriostatic water, 1–2 mL

Bacteriostatic water

Timing

Local SQ to injury site preferred (anecdotal)

Systemic SQ also used; oral bioavailability shown in animal studies.

Pre-sleep, fasted preferred

Half-life

~30 min plasma (estimated)

Tissue half-life longer; mechanism may explain durable effect.

~12 min (plasma)Molteno 2013

Shorter than tesamorelin (~26 min) — simpler GHRH analogue.

04Side Effects & Safety

Parameter

BPC-157

Sermorelin

Injection site reaction

Mild irritation (anecdotal)

Mild erythema, transient pain

GI symptoms

None reported in PL-14736 Phase 2

—

Cardiovascular

Not reported

—

Cancer risk

Theoretical concern via VEGF angiogenesis pathwaySikiric 2018

Contraindicated in active malignancy (GH/IGF-1 axis)

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid — insufficient safety data

Avoid

Long-term safety

Unknown beyond Phase 2 trial duration

—

Drug interactions

None established

—

Flushing / headache

—

Common transient effect

IGF-1 elevation

—

Modest at standard doses

Glucose handling

—

Generally neutral

Absolute Contraindications

BPC-157

·Pregnancy / breastfeeding
·Known active malignancy (theoretical VEGF concern)

Sermorelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

BPC-157

·History of cancer
·Concurrent VEGF inhibitor therapy (theoretical)
·Acute thrombotic events

Sermorelin

·Untreated diabetes

05Administration Protocol

Parameter

BPC-157

Sermorelin

1. Reconstitution

Add 1–2 mL bacteriostatic water to a 5 mg vial. Roll gently; do not shake. Solution should be clear and colourless.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Injection site

Subcutaneous near the injury site is the most common anecdotal route. Systemic SQ (abdomen) also used. Rotate sites.

SQ — abdomen or thigh. Rotate sites.

3. Timing

No strict timing requirement. Most users dose once or twice daily, often morning + evening.

Pre-sleep, fasted.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate 2–8 °C, use within 30 days.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

27–31G insulin syringe, 4–8 mm. Local injection allows finer 31G.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

BPC-157

+ TB-500

Strong

View TB-500 →

BPC-157 and TB-500 (Thymosin β-4) target distinct healing axes: BPC-157 upregulates VEGF-driven angiogenesis and fibroblast migration; TB-500 increases actin remodelling and cell migration via the actin-sequestering β-thymosin domain. Stacked, they cover both vascular (BPC) and structural (TB-500) regeneration pathways. Anecdotally favoured for tendon and ligament repair where both pathways contribute.

BPC-157: 250–500 mcg SQ · daily
TB-500: 2 mg SQ · 2× per week
Primary benefit: Tendon/ligament/muscle repair via complementary angiogenesis + migration

Sermorelin

+ Ipamorelin

Strong

View Ipamorelin →

Sermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.

Sermorelin: 200–300 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Raun 1998 Walker 1994